You are here: Industry Insights > Gilead Sciences

News List

Gilead announces primary endpoints met in Phase III remdesivir trial europeanpharmaceuticalreview
April 30, 2020
Gilead has said that topline results for clinical recovery have been demonstrated in a Phase III trial of remdesivir, tested in COVID-19 patients.
Gilead supersizes remdesivir trials, changes primary endpoint fiercebiotech
April 10, 2020
Gilead Sciences has made major mid-study changes to its global remdesivir trials, quadrupling the enrollment target and switching the primary endpoint.
Gilead signs drug discovery deal with Second Genome pharmaceutical-technology
April 08, 2020
Gilead Sciences has entered a multi-programme agreement with Second Genome to discover targets and drug candidates for inflammatory bowel disease (IBD) treatment.
Gilead Requests Retraction of Orphan Designation for Remdesivir contractpharma
March 26, 2020
Seeks to waive all benefits amid growing concerns the specialty status could impact pricing and availability of competitor products.
Gilead gets FDA approval for Epclusa to treat hepatitis C in children pharmaceutical-technology
March 23, 2020
Gilead Sciences has received approval from the US Food and Drug Administration (FDA) to use Epclusa for treating chronic hepatitis C infection (HCV) in children aged six years and above.
Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion biospace
March 04, 2020
Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards.
Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV) Gilead Sciences
February 01, 2020
Gilead Sciences today issued the following statement the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV).
Gilead Sciences submits NDA to treat RA in Japan biospectrumasia
October 10, 2019
Gilead Sciences, Inc. has announced the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis (RA) has been submitted to the Japanese Ministry of Health, Labor a
China NMPA approves Biktarvy to treat HIV-1 Infection biospectrumasia
August 18, 2019
Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks
Gilead Sciences, Renown Institute for Health Innovation collaborate for NASH biospectrumasia
July 16, 2019
Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000

Previous page 1 2 3 4 5 Next page